ARID1A-mutated ovarian cancers depend on HDAC6 activity.
ARID1A-mutated ovarian cancers depend on HDAC6 activity.
复制标题
DOI:
10.1038/ncb3582
复制
发表时间:
2017-08
影响因子:
21.3
通讯作者:
Zhang R
中科院分区:
文献类型:
--
作者:
Bitler BG;Wu S;Park PH;Hai Y;Aird KM;Wang Y;Zhai Y;Kossenkov AV;Vara-Ailor A;Rauscher FJ III;Zou W;Speicher DW;Huntsman DG;Conejo-Garcia JR;Cho KR;Christianson DW;Zhang R
ARID1A , encoding a subunit of the SWI/SNF chromatin-remodelling complex, is the most frequently mutated epigenetic regulator across all human cancers. ARID1A and TP53 mutations are typically mutually exclusive. Therapeutic approaches that correlate with this genetic characteristic remain to be explored. Here, we show that HDAC6 activity is essential in ARID1A-mutated ovarian cancers. Inhibition of HDAC6 activity using a clinically applicable small molecule inhibitor significantly improved the survival of mice bearing ARID1A-mutated tumours. This correlated with the suppression of growth and dissemination of ARID1A-mutated, but not wildtype, tumours. The dependence on HDAC6 activity in ARID1A-mutated cells correlated with a direct transcriptional repression of HDAC6 by ARID1A. HDAC6 inhibition selectively promoted apoptosis of ARID1A-mutated cells. HDAC6 directly deacetylates Lys-120 of p53, a pro-apoptotic post-translational modification. Thus, ARID1A mutation inactivates p53’s apoptosis-promoting function by upregulating HDAC6. Together, these results indicate that pharmacological inhibition of HDAC6 is a therapeutic strategy for ARID1A-mutated cancers.
登录
查看更多内容
影响因子:
64.5
作者:
Kawaguchi, Y;Kovacs, JJ;Yao, TP
通讯作者:
Yao, TP
影响因子:
30.8
作者:
Kadoch, Cigall;Hargreaves, Diana C.;Hodges, Courtney;Elias, Laura;Ho, Lena;Ranish, Jeff;Crabtree, Gerald R.
通讯作者:
Crabtree, Gerald R.
影响因子:
4.8
作者:
Debnath, J;Muthuswamy, SK;Brugge, JS
通讯作者:
Brugge, JS
影响因子:
10.3
作者:
Guan, Bin;Rahmanto, Yohan Suryo;Shih, Ie-Ming
通讯作者:
Shih, Ie-Ming
影响因子:
14.8
作者:
Hai Y;Christianson DW
通讯作者:
Christianson DW